Eton Pharmaceuticals, Inc. (NASDAQ: ETON) shares are experiencing a notable market response following the announcement of an asset acquisition. As of the most recent market check, the stock was surging 9.43% to trade at $6.50. The announcement of an asset acquisition agreement to buy Increlex (mecasermin injection) from Ipsen S.A. corresponded with this upward rise, with deal anticipated to be completed by the end of 2024.
ETON Strategically Concentrating on Rare Disease
Eton Pharmaceuticals is committed to developing and distributing drugs that can dramatically enhance the quality of life for patients with rare diseases. The acquisition of the medication Increlex, which is meant for individuals with severe primary insulin-like growth factor 1 deficiency (SPIGFD), bolsters this strategic focus.
Because of this ultra-rare illness, Increlex is an essential tool for individuals whose levels of insulin-like growth factor 1 are insufficient. The acquisition of this product enhances the company’s capacity to provide underprivileged and specialty patient populations with care.
Raising Awareness and Making Sure Care Is Continued
ETON has pledged to work closely with Ipsen to guarantee that patients everywhere will always have access to Increlex. This collaboration will help maintain consistency in care for those reliant on this essential treatment.
Global Reach and Future Commercialization
Increlex is currently approved for use in 40 territories, including the United States and the European Union. With an estimated 200 patients in the U.S. and 900-1,000 in Europe suffering from SPIGFD, Increlex remains the only treatment approved by both the FDA and EMA. Following the closing of the acquisition, Eton Pharmaceuticals will begin immediate commercialization of the product in the U.S.
Ipsen will continue to manage international distribution for six months, ensuring a seamless transition before the company takes full responsibility. Eton plans to finance the acquisition through existing cash reserves and an expanded credit facility with SWK Holdings. Ipsen’s global sales for Increlex reached €17.3 million in 2023.
